What is the best toxicity data to quote to patients for prostate IMRT vs nerve-sparing prostatectomy?

The surgery vs. RT question is a common one during a “2nd opinion” consultation with radiation oncology. More and more comparative data are being published regarding disease outcomes but many fewer exist regarding toxicity. I often hand out a copy of Sanda et al, NEJM 2008, which reports on qual...

Having a firm understanding of robust toxicity data, such as the Sanda et al paper recommended by Stan (median f/u 30 months), is indeed important for discussions with colleagues, debate at tumor boards, and counseling intelligent patients. I also like the Resnick et al paper (NEJM 2013, ncbi.nlm.ni...